尿液中PCA3 mRNA水平在前列腺癌诊断中的应用
Urine PCA3 mRNA level in diagnostic of prostate cancer.
作者信息
Li Meifeng, Zhou Dong, Zhang Weili, Gao Song, Zhou Xiaoqing
机构信息
Department of Urology, Lishui People's Hospital, The 6th Affiliated Hospital of Wenzhou Medical University, Zhejiang Province, PR China.
出版信息
J Cancer Res Ther. 2018;14(4):864-866. doi: 10.4103/jcrt.JCRT_734_17.
OBJECTIVE
The objective of this study is to evaluate the diagnostic effects of urine PCA3 mRNA level in patients with prostate cancer (PC).
METHODS
Twenty four patients with pathologically confirmed PC, 40 patients with benign prostatic hyperplasia (BPH), and 13 patients with urolithiasis were recruited in this study. The urine level of PCA3 mRNA was determined with real-time polymerase chain reaction and compared among the three groups. With the reference parameter of urine PCA3 mRNA, the diagnostic sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) were calculated.
RESULTS
The mRNA level in urine of PC, BPH and urolithiasis were 60.2 ± 32.2, 17.1 ± 12.9, and 6.2 ± 3.1, respectively, indicating that mRNA level in PC was significantly higher than that of in other two groups (P < 0.05). The AUC was 0.90 while the sensitivity and specificity were 87.5% and 79.2% with the cutoff value of 33.86.
CONCLUSION
The urine PCA3 mRNA could be a biomarker for diagnosing patients with PC.
目的
本研究旨在评估尿液中PCA3 mRNA水平对前列腺癌（PC）患者的诊断作用。
方法
本研究招募了24例经病理确诊的PC患者、40例良性前列腺增生（BPH）患者和13例尿路结石患者。采用实时聚合酶链反应测定三组患者尿液中PCA3 mRNA水平并进行比较。以尿液PCA3 mRNA为参考参数，计算诊断敏感性、特异性及受试者工作特征曲线下面积（AUC）。
结果
PC组、BPH组和尿路结石组患者尿液中mRNA水平分别为60.2±32.2、17.1±12.9和6.2±3.1，表明PC组mRNA水平显著高于其他两组（P<0.05）。AUC为0.90，当临界值为33.86时，敏感性和特异性分别为87.5%和79.2%。
结论
尿液PCA3 mRNA可作为诊断PC患者的生物标志物。
Zotero 插件